AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05463055 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy System (ProBeam)
Description: All of subjects (tumor patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors) will be treated with Proton radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months ( for this trial). Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.
Study NCT05215847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARD-101
Description: Twice daily, oral administration
Study NCT05983302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma-Fibrin Glue
Description: The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
Study NCT05080543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin 20% and terlipressin
Description: Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
Study NCT05080543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin 20% and terlipressin
Description: Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
Study NCT05286684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Consultation
Description: History of the disease, anatomopathological and molecular biological data concerning the initial tumor; Collection of treatments received and/or in progress by the patient for her meningeal tumor (chemotherapy, targeted therapy, radiotherapy, surgery, corticosteroids, antiepileptics); Evaluation of the general condition and neurological status.
Study NCT05286684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral and medullary MRI, lumbar puncture, CSF sampling
Description: diagnosis of leptomeningeal involvement
Study NCT05286684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological test
Description: 5 ml of additional CSF after diagnostic lumbar puncture for proteomic analysis, 50-100 µl of breast aspiration fluid (NAF) for patients with an existing breast tumor, for proteomic analysis 10 ml of blood for proteomic analysis
Study NCT06169423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educative intervention
Description: an activity for simulation-based learning First, a theoretical session was carried out in order to acquire theoretical knowledge, skills to provide support for perinatal grief, and improve self-awareness. Prior to this, a pre-questionnaire was carried out in order to previously evaluate these aspects.~Subsequently, a first session was held to make contact with the simulation, teach the scenarios, material, etc. After this, two questionnaires were passed: one related to the acquisition of knowledge, skills to provide support, self-awareness and another on the students' satisfaction with the simulation.
Study NCT05107934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104
Description: solution for subcutaneous injection, 40 mg/mL
Study NCT05107934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride solution for Injection
Study NCT05803499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Behavior Therapy for Insomnia
Description: This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.
Study NCT05803499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information-Only Control
Description: The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.
Study NCT05826158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
Description: 18F-mFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
Study NCT04202211 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT oral
Description: lyophilized FMT given orally (10 capsules) twice weekly for total of 8 weeks
Study NCT04202211 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT enema
Description: lyophilized FMT given via enema (1) twice weekly for total of 8 weeks
Study NCT04202211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral
Description: placebo given orally (10 capsules) twice weekly for total of 8 weeks
Study NCT04202211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo enema
Description: placebo given via enema (1) twice weekly for total of 8 weeks
Study NCT04202211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enema
Description: placebo given via enema (1) twice weekly for total of 8 weeks
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T17
Description: Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T17
Description: Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin≥1000mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin≥1000mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 15mg Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30mg Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04885712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT05014230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Open Placebo
Description: Zeebo
Study NCT05014230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid medication as part of standard care
Description: Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
Study NCT05014230 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Opioid medication as part of standard care
Description: Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
Study NCT05071833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peppermint oil.
Description: Peppermint oil.
Study NCT05071833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06066931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plastic surgery of the pelvic floor and perineal wound with counter-displaced skin-subcutaneous fascial flaps after extralevatory abdominal-perineal extirpation of the rectum
Description: Skin-subcutaneous fascial flap on the leg is cut out from one side of the perineal wound, and deepithelized, forming a diamond-shaped perineal wound. The cut flap is immersed in the aperture of the pelvis and fixed with single sutures to the remains of levators of the opposite side. The flap width should be 3-4 cm, sufficient to fill the pelvic aperture. On the opposite side of the wound, a skin-subcutaneous fascial flap is cut out on a triangular leg equal to the width of the previously formed diamond-shaped wound. The flap is moved to the center of the wound, additionally filling wound cavity with it, combining the vertex of the triangle with the vertex of the rhombus. The perineal wound is drained through the contraperture. The flap is fixed with separate nodal seams.
Study NCT06066931 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plastic surgery of the pelvic floor and perineal wound with local tissues
Description: Simple layer-by-layer suturing of the sciatic-anal and subcutaneous adipose tissue is performed using nodular sutures. The skin was sewn up with nodular sutures at the discretion of surgeons. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon.
Study NCT06066931 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plastic surgery of the pelvic floor and perineal wound with mesh endoprosthesis
Description: A mesh allograft with an adhesive coating is inserted into the bottom of the wound, positioned horizontally between the inner surfaces of the ischial bones and vertically between the sacrum and the vagina in women or between the sacrum and the prostate gland in men. The mesh was sewn from behind on both sides of the coccyx or sacrum. From the side, the mesh was attached to the remainder of the levator muscle and from the front to the transverse muscles of the perineum. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon. The sciatic-anal and subcutaneous fat are sutured using nodular sutures.
Study NCT06395714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personnalized physiotherapy
Description: Following completion of the ankle go test, patients in experimental group will receive specific instructions for continuing their rehabilitation, which will be passed on to the physiotherapist responsible for the rehabilitation.
Study NCT06395714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy
Description: Following completion of the ankle go test, patients in active comparator group will receive usual physiotherapy
Study NCT04630626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplify Disc
Description: The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
Study NCT04630626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ACDF
Description: Historical ACDF control data
Study NCT04880889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL 3000
Description: capsule 500 mg
Study NCT04880889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Pantogar
Description: capsule
Study NCT04880889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BL3000 Placebo
Description: capsule 500 mg
Study NCT04880889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantogar - Placebo
Description: capsule
Study NCT06092957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin-based induction chemotherapy
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
Study NCT06092957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-based induction chemotherapy
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
Study NCT06092957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full course of PD-1/PD-L1 blockades
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
Study NCT06092957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full course of PD-1/PD-L1 blockades
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
Study NCT06092957 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced-dose IMRT
Description: GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy
Study NCT06092957 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose IMRT
Description: GTVnx：69.96Gy/33Fr/2.12Gy；CTV1：60.60Gy/33Fr/1.82y；CTV2：54.12Gy/33Fr/1.64Gy
Study NCT06092957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles
Study NCT06092957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles
Study NCT05232305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Peel
Description: Standard bread and test breads (with added pomegranate peel) to be used in the study will be produced by Asst. Prof. Özlem ÖZPAK AKKUŞ in the Nutrition Principles Laboratory of Toros University. For standard bread, 900 ml of water, 42 fresh yeast, 12 g of salt and 12 g of sunflower oil will be added to 1000 g of sifted whole wheat flour and the prepared bread mixture will be divided into 40 equal parts. To make bread with pomegranate peel added, 1000 g of sifted whole wheat flour, 20 g of pomegranate peel powder, 914 ml of water, 42 g of fresh yeast, 12 g of salt and 12 g of sunflower oil will be added and the prepared bread mixture is divided into 40 equal parts with 500 mg of pomegranate peel powder in each piece).
Study NCT05137145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
Study NCT06628024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Milk
Description: Milk
Study NCT06628024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoghurt
Description: Yoghurt
Study NCT05137145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Polyethylene Glycol Electrolyte Powder
Description: The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
Study NCT05884957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Nitric oxide synthase gene
Description: Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.
Study NCT05884957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide synthase gene
Description: Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.
Study NCT04849000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: SHR-1209
Study NCT04849000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1209 Placebo
Description: SHR-1209 Placebo
Study NCT05072535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet B
Description: HA121-28 tablet B 200 mg
Study NCT05072535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet A
Description: HA121-28 tablet A 200 mg
Study NCT05983302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repairing Gel
Description: The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
Study NCT05983302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repairing Gel and Platelet-Rich Plasma-Fibrin Glue
Description: The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
Study NCT05233722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
Study NCT05233722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
Study NCT05233722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Description: 2 hours of Euglycemic Hyperinsulinemic Clamp
Study NCT05233722 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Insulin infusion
Description: 2 hours of Euglycemic Hyperinsulinemic Clamp
Study NCT05233722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 800 mg of calcium tablets
Study NCT05233722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Administration of 16 mg of Rapamycin tablets
Study NCT05244876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back school
Description: Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
Study NCT05290896 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Phacoemulsification
Description: Phacoemulsification for senile cataract.
Study NCT04154488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavorixafor
Description: Mavorixafor capsules will be administered per dose and schedule specified in the arm.
Study NCT05983302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical wound irrigation (control)
Description: For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
Study NCT06202989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiprofen-CC™ plus standard treatment
Description: Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery
Study NCT06202989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard treatment
Description: The placebo is the base cream with no medicinal ingredients to be applied 3 times per day for 6 weeks after surgery
Study NCT06343883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - low pressure
Description: low-intensity focused ultrasound applied to the S1.
Study NCT06343883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - medium pressure
Description: low-intensity focused ultrasound applied to the S1.